---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-012218"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:05:59.095318+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Biostage reports Q2 2022 net loss of $1.3M; raises $5.1M in private placement

## Summary
- Net loss of $1.3M ($0.12 per share) vs $0.4M loss in Q2 2021; increase due to higher legal costs and prior-year PPP loan forgiveness.
- Completed private placement in May 2022, generating net proceeds of ~$5.1M to fund clinical development of Biostage Esophageal Implant (BEI).
- Operating cash on-hand of $4.6M as of June 30, 2022; expected runway into Q2 2023.
- Executed settlement with Harvard Bioscience and plaintiffs in wrongful death litigation; no admission of liability.

## SEC filing metadata
- accession: 0001558370-22-012218
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000155837022012218/0001558370-22-012218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000155837022012218/tmb-20220804x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-012218
- JSON: https://secwatch.observer/filing/0001558370-22-012218.json
- Plain text: https://secwatch.observer/filing/0001558370-22-012218.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.